Characteristics ALC-15/AMC-15 ≥ 1 (N = 120) ALC-15/AMC-15 < 1 (N = 136) P-value
At Diagnosis      
Age, years, median (range) 55 (22-76) 55 (17-76) 0.2
Gender     0.4
Male 71 (59.0%) 87 (64.0%)  
Female 49 (41.0%) 49 (36.0%)  
Extra-nodal sites     0.6
0 81 (67.5%) 90 (66.2%)  
1 31 (26.0%) 33 (24.3%)  
2 6 (5.0%) 11 (8.1%)  
3 2 (1.5%) 1 (0.7%)  
4 0 (0.0%) 1 (0.7%  
LDH (U/L), median (range) 211 (110-2400) 284 (111-2250) 0.3
PS     0.1
0 33 (27.5%) 23 (17.0%)  
1 85 (70.8%) 107 (78.6%)  
2 2 (1.7%) 6 (4.4%)  
Stage     0.9
I 13 (10.8%) 19 (14.0%)  
II 21 (17.5%) 22 (16.2%)  
III 26 (21.7%) 31 (22.8%)  
IV 60 (50.0%) 64 (47.0%)  
IPI risk factors      
Age, years     0.1
>60 38 (31.7%) 56 (41.7%)  
≤ 60 82 (68.3%) 80 (58.8%)  
Extra-nodal sites     0.5
> 1 8 (6.7%) 13 (9.6%)  
≤ 1 112 (93.3%) 123 (90.4%)  
LDH     <0.04
abnormal 51 (42.5%) 75 (55.2%)  
normal 69 (57.5%) 61 (44.8%)  
PS     0.3
> 1 2 (1.7%) 6 (4.4%)  
≤ 1 118(98.3%) 130 (95.6%)  
Stage     0.8
I/II 34 (28.0%) 41 (30.0%)  
III/IV 86 (72%) 95 (70.0%)  
IPI score     0.1
0 17 (14.0%) 15 (11.0%)  
1 44 (37.0%) 35 (26.0%)  
2 41 (34.0%) 60 (44.0%)  
3 14 (12.0%) 24 (18.0%)  
4 4 (3.0%) 2 (1.0%  
IPI     <0.03
≥ 2 59 (49.0%) 86 (63.0%)  
< 2 61 (51.0%) 50 (37.0%)  
At relapse      
IPI risk factors      
Age-R     0.2
> 60 41 (35%) 57 (42%)  
≤ 60 79 (65%) 79 (58%)  
Extra nodal sites-R     < 0.01
> 1 7 965) 22 (16%)  
≤ 1 113 (94%) 114 (84)  
LDH-R     <0.0001
abnormal 40 (33%) 80 (59%)  
normal 80 (67%) 56 (41%)  
PS-R     < 0.02
> 1 8 (7%) 22 (16%)  
≤ 1 112 (93%) 114 (84%)  
Stage-R     <0.03
I/II 60 (50%) 49 (36%)  
III/IV 60 (50%) 87 (64 %)  
IPI-R     <0.0004
>2 16 (13%) 44 (32%)  
≤ 2 104 (87 %) 92 (68%)  
Pre-transplant Rituximab     0.3
No 61 (515) 76 (56%)  
Yes 59 (49%) 60 (445)  
Number of prior treatments before transplant     0.1
2 108 (90%) 112 (81%)  
3 10 (8%) 23 (17%)  
4 2 (2%) 1 91%)  
At transplant      
Age, years, median (range) 55.5 (22-77) 59 (17-76) 0.2
Outcome prior to transplant     <0.02
CR 39 (33.0%) 27 (20.0%)  
PR 81 (67.0%) 109 (80.0%)  
Conditioning regimens     0.7
CTX/TBI 2 (2.0%) 4 (3.0%)  
BEAC 21 (18.0%) 26 (19.0%)  
BEAM 97 (80.0%) 106 (78.0%)  
Infused CD34, median (range) 3.56 (2.0-14.85) 3.14 (2.0-11.06) 0.4
Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse; PS = performance status; PS-R; performance status at relapse; Stage-R = stage at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic Index at relapse; CTX= cyclophosphamide; TBI = Total body irradiation: BEAC = BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM = BCNU, etoposide, Ara-C, and melphalan; CR = complete remission; PR = partial response.
Table 2: Patientsí characteristics based on the ALC-15/AMC-15 ratio = 1 versus < 1.